13F Holdings
中文EN

ELTP ELITE PHARMACEUTICALS INC /NV/

Pharmaceutical Preparations · OTC · SEC CIK 1053369 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.8%
TTM net income YoY333.0%
TTM EPS YoY50.0%
Revenue 3-yr CAGR52.2%
Net income 3-yr CAGR50.1%

Margins

Gross margin43.7%
Operating margin25.3%
Net margin41.6%
FCF margin6.0%
EBITDA margin26.1%

Returns

ROE65.6%
ROA46.1%
ROIC (approx.)52.7%
Asset turnover1.11x

Leverage & solvency

Liabilities / assets15.3%
Debt / equity0.00x
Current ratio6.65x
Interest coverage338.18x

Cash quality & payout

Operating cash flow / net income0.18x
Accruals ratio37.8%
Payout ratio—
Capex / revenue1.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31
Income statement
Revenue$148.87M$84.04M$56.63M$34.16M$32.26M
Cost of revenue$73.85M$43.96M$30.27M$17.56M$17.47M
Gross profit$75.02M$40.09M$26.36M$16.59M$14.80M
R&D expense$5.74M$7.96M$6.88M$6.20M$4.05M
SG&A expense$17.60M$9.00M$7.15M$5.12M$4.46M
Operating income$49.11M$19.60M$10.79M$3.68M$5.07M
Interest expense$111,361$128,234$137,438$1.11M$191,816
Pretax income$56.81M-$52,140$463,092$3.99M$6.30M
Income tax$11.94M$4.26M-$19.65M$424,028-$1.74M
Net income$44.87M-$4.31M$20.11M$3.56M$8.90M
EBITDA$50.18M$20.83M$12.11M$4.95M$6.28M
EPS (basic)0.040.000.020.000.01
EPS (diluted)0.030.000.020.000.01
Weighted avg. shares (diluted)1.14B1.07B1.02B1.01B1.01B
Balance sheet
Cash & equivalents$29.80M$11.77M$7.54M$7.83M$8.54M
Receivables$59.72M$29.21M$19.45M$3.09M$3.06M
Inventory$21.26M$16.24M$12.93M$9.55M$6.74M
Current assets$112.11M$57.74M$40.01M$21.51M$18.86M
PP&E, net$10.18M$10.33M$10.18M$10.43M$5.95M
Intangibles$4.79M$5.64M$6.34M$6.34M$6.63M
Total assets$138.29M$96.39M$83.65M$40.90M$35.15M
Current liabilities$17.39M$11.84M$13.05M$7.83M$6.69M
Long-term debt————$1.25M
Total debt————$1.25M
Total liabilities$39.41M$42.87M$26.07M$11.94M$9.93M
Shareholders' equity$98.88M$53.52M$57.58M$28.96M$25.22M
Net debt————-$7.29M
Shares outstanding1.08B1.07B1.07B1.01B1.01B
Cash flow statement
Operating cash flow$23.75M$7.46M-$3.24M$3.34M$6.51M
Capital expenditure$925,626$1.63M$809,653$5.74M$498,566
Free cash flow$22.82M$5.83M-$4.04M-$2.40M$6.01M
Investing cash flow-$925,626-$2.40M-$809,653-$5.74M-$498,566
Financing cash flow-$4.32M-$825,740$3.34M$1.70M-$667,133
Depreciation & amortization$1.07M$1.23M$1.32M$1.28M$1.21M
Stock-based compensation$176,507$227,565$159,921$39,325$14,353

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.